melanocortin receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-09. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
== See also == Lysergamide § Related compounds Substituted isotryptamine List of investigational hallucinogens and entactogens List of miscellaneous 5-HT2A receptor agonists Non-hallucinogenic 5-HT2A receptor agonist BOL-148 (2-bromo-LSD) and SPT-348 SDZ SER-082 DLX-0002700 LEK-8829 LSD-Quinoline
The 800-page "Doping in Germany from 1950 to today" study details how the West German government helped fund a wide-scale doping programme. West Germany encouraged and covered up a culture of doping across many sports for decades. Clemens Prokop, head of Germany's athletics federation, told Reuters Television in an interview, "It is a bit of a problem that there is a short version that has been published and that names have not been named." Immediately after the 1954 FIFA World Cup Final, rumors emerged that the West German team had taken performance-enhancing substances. Several members of the team fell ill with jaundice, presumably from a contaminated needle. Members of the team later claimed they had been injected with glucose, and the team physician Franz Loogen said in 2004 that the players had only been given Vitamin C before the game. A Leipzig University study in 2010 posited that the West German players had been injected with the banned substance methamphetamine. According to the German Olympic Sports Association (DOSB), doping was common in the West German athletes of the 1980s. West German heptathlete Birgit Dressel died at age 26 due to sudden multiple organ failure, triggered at least in part by long-term steroid abuse. In the newly emerging doping discussion in 2013 after submission of the final report of the anti-doping commission, the former German sprinter Manfred Ommer accused the Freiburg physician Armin Klümper: "Klümper was the largest doper on this planet."
Even moderate sustained use of alcohol may increase anxiety and depression levels in some individuals. In most cases these drug induced psychiatric disorders fade away with prolonged abstinence. A protracted withdrawal syndrome can also occur with psychiatric and other symptoms persisting for months after cessation of use. Among the currently prevalent medications, benzodiazepines are the most notable drug for inducing prolonged withdrawal effects with symptoms sometimes persisting for years after cessation of use. Prospective epidemiological studies do not support the hypotheses that comorbidity of substance use disorders with other psychiatric illnesses is primarily a consequence of substance use or dependence or that increasing comorbidity is largely attributable to increasing use of substances. Yet emphasis is often on the effects of substances on the brain creating the impression that dual disorders are a natural consequence of these substances. However, addictive drugs or exposure to gambling will not lead to addictive behaviors or drug dependence in most individuals but only in vulnerable ones, although, according to some researchers, neuroadaptation or regulation of neuronal plasticity, and molecular changes, may alter gene expression in some cases and subsequently lead to substance use disorders. Research instruments are also often insufficiently sensitive to discriminate between independent, true dual pathology, and substance-induced symptoms.
== MD Curriculum == In August 2023, the UNC School of Medicine launched the second version of its Translational Education at Carolina (TEC) curriculum, known as TEC 2.0. The original TEC curriculum, first implemented in 2014, is designed to integrate basic science courses with longitudinal patient care, allowing students to gain clinical experience earlier than in traditional curricula. It consists of three key phases through which medical students progress.
HBTU (hexafluorophosphate benzotriazole tetramethyl uronium) is a coupling reagent used in solid phase peptide synthesis. It was introduced in 1978 and shows resistance against racemization. It is used because of its mild activating properties. HBTU is prepared by reaction of hydroxybenzotriazole with TCFH under basic conditions and was assigned to a uronium type structure, presumably by analogy with the corresponding phosphonium salts, which bear a positive carbon atom instead of the phosphonium residue. Later, it was shown by X-ray analysis that salts crystallize as guanidinium rather than the corresponding uronium salts.
Sources: en.wikipedia.org
=== Articular cartilage === Cartilage is an avascular, aneural and alymphatic tissue within the body. The extracellular matrix (ECM) of collagen is what gives it its high strength. The figure below shows the components of the ECM.
== Uses == Aside from its major role in the functioning of living organisms, pyruvic acid is of interest as a reagent in the synthesis of specialized organic compounds as discussed above in the reactivity section.
Hosokawa Micron Powder Systems is an American company located in Summit, New Jersey, which designs and manufactures equipment for size reduction, classification and mixing of chemical, pharmaceutical and food materials. The company was started in 1923 by Louis Ruprecht named Pulverizing Company and was later bought by the Hosokawa Micron Group in 1985.
===== Drug trafficking ===== 17 November 2013: Yong Vui Kong, a Malaysian found guilty of drug trafficking in 2007 and sentenced to death in 2008. He lost multiple appeals against his sentence to the Court of Appeal and President of Singapore. However, when changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced to life imprisonment and 15 strokes of the cane. Yong was the first drug convict on death row to be spared the gallows since the 2013 law reforms. 6 January 2014: Subashkaran Pragasam, a Singaporean found guilty of trafficking heroin in 2008 and sentenced to death in 2012. When changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced in 2014 to life imprisonment and 15 strokes of the cane. 3 March 2014: Dinesh Pillai Reja Retnam, a Malaysian found guilty of trafficking heroin in 2009 and sentenced to death in 2011. When changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced in 2014 to life imprisonment on the grounds of diminished responsibility due to him suffering from depression when he committed the crime. 27 May 2014: Yip Mun Hei, a Singaporean convicted of trafficking heroin in 2008 and sentenced to death in 2009. When changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced in 2014 to life imprisonment and 15 strokes of the cane. He had an accomplice Leong Soy Yip (also sentenced to death) whose fate remains unknown.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.